<p>Disclosed is a therapeutic agent for interstitial pneumonia, which ensures to exert the effect of superoxide dismutase (SOD) contained therein. Specifically disclosed is a therapeutic agent for interstitial pneumonia, which comprises 10 to 100 mg of lecithin-conjugated superoxide dismutase represented by the general formula (I), which further comprises sucrose for the purpose of increasing its stability, and which has a dosage form suitable for intravenous administration. SOD'(Q-B)<SUB>m</SUB> (I) wherein SOD' represents a residue of superoxide dismutase; Q represents a chemical crosslink; B represents a residue produced by removing a hydrogen atom from a hydroxy group in lysolecithin which has the hydroxy group at position-2 of a glycerol moiety therein; and m represents an average number of lysolecithin molecules bound to one superoxide dismutase molecule and is an integer of 1 or greater.</p>
